Renovo Group PLC operates in the Commercial physical research sector. Renovo Group plc is a biopharmaceutical product company developing a portfolio of products, which exploit different mechanisms of action to reduce scarring and stimulate tissue regeneration at multiple body sites. It has four products in clinical development: Juvista Economic Union and the United States for improvement of appearance of scars in skin and is in Phase III and II trial respectively; Adaprev is a medical device for reduction of adhesions and improvement of tendon function in patients undergoing surgical repair of lacerated flexor tendons in hand; Prevascar is a pharmaceutical drug for reduction of skin scarring, and Juvidex is a cosmetic ingredient accelerating wound healing. RN1005 is a pre-clinical drug for prevention of scarring and enhance tissue regeneration. During the fiscal year ended September 30, 2010, it completed recruitment of first Juvista Economic Union Phase III trial and developed new single dose formulation (Juvista Paediatric), which is in clinical trial. In our complete report available for purchase the company is compared to: Antisoma PLC, Proteome Sciences PLC and GW Pharmaceuticals PLC.